Metabolomics and risk of Parkinson's Disease

 描述（由申请人提供）：帕金森病（PD）是美国第二常见的神经退行性疾病，影响超过100万美国人;由于人口老龄化，这一数字正在增长。目前的治疗不能阻止疾病进展，最终导致严重残疾。因此，迫切需要开发神经保护治疗。因为在临床诊断PD时，已经存在大量神经元损失，所以理想情况下应更早开始此类治疗。宗旨 拟议的研究是实施和验证一种新的代谢组学方法，用于识别临床前或运动前PD患者外周血的早期变化。 代谢组学结果将与前瞻性收集并定期更新的PD风险因素的详细和经验证信息相结合。我们期望通过这种方法来确定PD病因的新线索，并确定可能有助于早期诊断的PD代谢组学特征。为了实现这些目标，我们将利用从三个大型正在进行的队列中收集的80，000多名参与者的数据和血液样本，护士健康研究（NHS），健康专业人员随访研究（HPFS）和癌症预防研究-II营养，他们已经对帕金森病事件进行了超过25年的随访。我们预计将包括共805例PD事件病例，将匹配到805个对照，使用巢式病例对照设计。

 DESCRIPTION (provided by applicant): Parkinson disease (PD) is the second most common neurodegenerative disease in the United States and affects over one million Americans; this number is growing due to population aging. Current treatments do not prevent the disease progression that ultimately results in severe disability. There is thus a compelling need to develop neuroprotective treatments. Because at the time of the clinical diagnosis of PD there is already substantial neuronal loss, such treatments should ideally be initiated earlier. Aims of the proposed investigation are to implement and validate a novel metabolomic approach for the identification of early changes in peripheral blood of individuals with preclinical or premotor PD. The metabolomic results will be integrated with detailed and validated information on risk factors for PD, which has been collected prospectively and periodically updated. We expect by this means to identify new clues to the etiology of PD and to identify a metabolomic signature of PD that could contribute to an early diagnosis. To achieve these goals, we will take advantage of data and blood samples collected from over 80,000 participants in three large ongoing cohorts, the Nurses' Health Study (NHS), the Health Professional Follow-up Study (HPFS), and the Cancer Prevention Study-II Nutrition, who have been followed for over 25 years for incident Parkinson disease. We expect to include a total of 805 incident cases of PD that will be matched to 805 controls, using a nested case-control design.